摘要
目的 观察他克莫司 (FK5 0 6 )作为免疫抑制剂的有效性和安全性。方法 将首次接受同种异体肾移植的 35例患者随机分为 2组 ,一组给予他克莫司、硫唑嘌呤 (或霉酚酸酯 )和泼尼松(FK5 0 6组 ) ,另一组给予环孢素A、硫唑嘌呤 (或霉酚酸酯 )及泼尼松 (CsA组 ) ,观察 2个组的免疫抑制效果及药物的副作用。结果 CsA组和FK5 0 6组的人 /肾 1年存活率分别为 10 0 .0 % / 93 .3 %和95 .0 % / 95 .0 % ;两组肝和肾的功能、血糖、血钾的差异无显著性 ;FK5 0 6组的血脂及收缩压明显低于CsA组 ;FK5 0 6组的碱性磷酸酶升高的发生率较CsA组高 ,差异有显著性 (P <0 .0 5 )。结论 他克莫司是肾移植术后强有力的免疫抑制剂 ;与霉酚酸酯联合用药可减少急性排斥反应的发生率目的 观察他克莫司 (FK5 0 6 )作为免疫抑制剂的有效性和安全性。方法 将首次接受同种异体肾移植的 35例患者随机分为 2组 ,一组给予他克莫司、硫唑嘌呤 (或霉酚酸酯 )和泼尼松(FK5 0 6组 ) ,另一组给予环孢素A、硫唑嘌呤 (或霉酚酸酯 )及泼尼松 (CsA组 ) ,观察 2个组的免疫抑制效果及药物的副作用。结果 CsA组和FK5 0 6组的人 /肾 1年存活率分别为 10 0 .0 % / 93 .3 %和95 .0 % / 95 .0 % ;两组肝和肾的功能、血糖、血钾的差异无显著性 ;FK5
Objectives To compare the effect and safety of tacrolimus (FK506) with cyclosporin (CsA) in renal transplantation. Methods A total of 35 first cadaveric kidney transplant recipients were randomized to receive FK506 based ( n =20) or CsA based ( n =15) triple therapy after transplantation. The immunosuppressive effects and side reactions were observed in both two groups. Results The 1 year person/graft survival rate in FK506 and CsA groups was 100.0% and 93.3%, 95.0% and 95.0% , respectively .The differences in liver and renal function, blood glucose and blood potassium between the two groups were not significant ( P > 0.05 ). In FK506 group blood lipid and systolic pressure were obviously lower and the incidence of alkaline phosphatase higher than in CsA group ( P < 0.05 ). Conclusions Tacrolimus is a safe and effective immunosuppressive agent. Combined use of FK506 with MMF may decrease the episodes of acute rejection.
出处
《中华器官移植杂志》
CAS
CSCD
2000年第3期149-150,共2页
Chinese Journal of Organ Transplantation
关键词
肾移植
免疫抑制剂
临床研究
他克莫司
Kidney transplantation
Immunosuppressive agents
Clinical studies
